GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Cyclically Adjusted Price-to-FCF

Eli Lilly and Co (BUE:LLY) Cyclically Adjusted Price-to-FCF : 228.32 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Price-to-FCF?

As of today (2024-05-21), Eli Lilly and Co's current share price is ARS15962.00. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ARS69.91. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is 228.32.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BUE:LLY' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.08   Med: 28.27   Max: 220.94
Current: 216.98

During the past years, Eli Lilly and Co's highest Cyclically Adjusted Price-to-FCF was 220.94. The lowest was 13.08. And the median was 28.27.

BUE:LLY's Cyclically Adjusted Price-to-FCF is ranked worse than
91.77% of 328 companies
in the Drug Manufacturers industry
Industry Median: 33.51 vs BUE:LLY: 216.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ARS310.228. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ARS69.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Price-to-FCF Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.22 44.71 68.58 84.88 164.46

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.20 109.24 137.06 164.46 215.53

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.



Eli Lilly and Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=15962.00/69.91
=228.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=310.228/131.7762*131.7762
=310.228

Current CPI (Mar. 2024) = 131.7762.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 24.124 100.560 31.613
201409 42.296 100.428 55.499
201412 21.538 99.070 28.648
201503 -15.652 99.621 -20.704
201506 20.080 100.684 26.281
201509 27.582 100.392 36.205
201512 21.484 99.792 28.370
201603 -20.518 100.470 -26.911
201606 61.004 101.688 79.054
201609 80.670 101.861 104.362
201612 91.879 101.863 118.861
201703 -38.584 102.862 -49.430
201706 89.186 103.349 113.717
201709 95.145 104.136 120.399
201712 91.478 104.011 115.897
201803 15.355 105.290 19.218
201806 -32.992 106.317 -40.893
201809 261.318 106.507 323.318
201812 121.835 105.998 151.465
201903 -14.190 107.251 -17.435
201906 148.099 108.070 180.587
201909 284.714 108.329 346.337
201912 427.559 108.420 519.665
202003 30.255 108.902 36.610
202006 592.894 108.767 718.316
202009 453.390 109.815 544.061
202012 354.493 109.897 425.069
202103 475.990 111.754 561.268
202106 517.852 114.631 595.304
202109 504.875 115.734 574.856
202112 768.995 117.630 861.478
202203 778.045 121.301 845.235
202206 197.081 125.017 207.737
202209 962.165 125.227 1,012.489
202212 758.873 125.222 798.594
202303 723.541 127.348 748.701
202306 -217.375 128.729 -222.521
202309 -2,818.424 129.860 -2,860.023
202312 -3,136.157 129.419 -3,193.268
202403 310.228 131.776 310.228

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (BUE:LLY) Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.